Synthetic data is moving from “privacy workaround” to a governed production asset. New medical evidence argues for generating full high-dimensional datasets, while policy and research communities are sharpening focus on bias, power, and self-training failure modes.
Impact of synthetic data generation for high-dimensional cross-sectional medical data: fidelity, utility, privacy, and the curse of dimensionality
JAMIA researchers evaluated 12 medical datasets across seven generative models to test how adding adjunct variables to core task variables changes synthetic data fidelity, utility, and privacy. Their finding: generating comprehensive, high-dimensional synthetic datasets preserved these properties better than producing low-dimensional subsets. The work directly challenges a common implementation shortcut—dropping “extra” features to simplify generation—by showing that simplification can degrade the very outcomes teams care about.
- For health-data platforms, “full schema” synthesis may be the safer default than task-only exports, especially when downstream analyses depend on correlated covariates.
- Data teams can use this as evidence when negotiating compute cost vs. utility tradeoffs with product and compliance stakeholders.
- Privacy assessments should be run on the same high-dimensional outputs intended for sharing, not on reduced feature sets that behave differently.
New project to investigate societal consequences of using synthetic data to train algorithms
The University of York announced SYNDATA, an ERC-funded project led by Dr. Benjamin Jacobsen, to study practical, ethical, and political impacts of synthetic data used for AI training in sectors including healthcare and finance. The project plans archival research, fieldwork, and case studies, focusing on how synthetic data is produced, what it represents, and how power dynamics shape outcomes. For practitioners, this signals that synthetic data pipelines will be evaluated not just on re-identification risk, but also on who is represented and who benefits.
- Expect increased scrutiny of provenance: how synthetic datasets are specified, labeled, and governed across organizations.
- Compliance and policy teams should prepare for questions about representational harms, not only privacy leakage.
Synthetic Data: The New Data Frontier
The World Economic Forum briefing paper positions synthetic data as a response to data scarcity, privacy constraints, and testing needs, with examples in healthcare and finance. It outlines generation methods, flags risks such as bias amplification, and recommends hybrid approaches plus governance and tailored regulation. The practical takeaway is procedural: treat synthetic data like a product with controls—documentation, risk reviews, and fit-for-purpose evaluation—rather than a one-off anonymization step.
- Leaders get a governance framing that aligns synthetic data with enterprise risk management and AI oversight.
- Hybrid strategies (real + synthetic) are positioned as a default to reduce brittleness and overfitting to synthetic artifacts.
NeurIPS 2025 Workshop on AI in the Synthetic Data Age: Challenges and Solutions
Rice University DSP announced a NeurIPS 2025 workshop focused on generative AI systems trained with synthetic data and the “self-consuming loop” problem, where iterative training on generated outputs can cause drift, reinforce bias, and degrade quality. The workshop aims to convene research on both the risks and mitigation approaches. For engineering teams, it’s a reminder that synthetic data is not automatically additive; feedback loops can turn it into a compounding error source.
- Teams building continuous training pipelines should explicitly monitor for drift and distribution collapse when synthetic data is in the mix.
- Evaluation suites need to test iterative-use scenarios, not just single-generation snapshots.
Addressing Bias in Imaging AI to Improve Patient Equity
RSNA highlighted an R&E Foundation grant project showing synthetic data can reduce bias in medical imaging AI by balancing underrepresented datasets, improving fairness and equity in diagnostics. The emphasis is on practical bias mitigation: using synthetic examples to fill gaps where real-world data collection is limited or uneven. This is also a compliance-adjacent use case—fairness work increasingly intersects with clinical validation expectations and risk management.
- Synthetic augmentation can be positioned as a targeted fairness intervention, not just a privacy tactic.
- Teams should document how synthetic samples were generated and validated to support auditability of bias mitigation claims.